Briefing
Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer.
A whole-genome tumor-informed assay tracking about 1,800 mutations was used on 227 plasma samples from 39 people with advanced cancer receiving immune checkpoint inhibitors, and 33% of positive detections were below 100 parts per million.
- Design: Evidence level 3
- Assay: NeXT Personal
NPJ Precision OncologyPubMed 41580469DOI 10.1038/s41698-026-01287-3